Creo Medical Group PLC (LON:CREO - Get Free Report)'s stock price rose 4.1% during mid-day trading on Monday . The stock traded as high as GBX 13.40 ($0.18) and last traded at GBX 13.40 ($0.18). Approximately 545,725 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 1,261,216 shares. The stock had previously closed at GBX 12.88 ($0.17).
Creo Medical Group Stock Performance
The stock has a market capitalization of £49.55 million, a PE ratio of -1.94 and a beta of 0.86. The company has a quick ratio of 2.19, a current ratio of 3.24 and a debt-to-equity ratio of 29.96. The firm has a 50 day moving average price of GBX 13.13 and a 200-day moving average price of GBX 14.16.
Creo Medical Group (LON:CREO - Get Free Report) last announced its quarterly earnings data on Monday, May 19th. The company reported GBX (8) (($0.11)) earnings per share (EPS) for the quarter. Creo Medical Group had a negative return on equity of 41.79% and a negative net margin of 73.93%. Research analysts expect that Creo Medical Group PLC will post -10.0800005 EPS for the current fiscal year.
Insider Transactions at Creo Medical Group
In related news, insider Kevin Crofton purchased 701,750 shares of the firm's stock in a transaction on Friday, May 30th. The stock was bought at an average cost of GBX 16 ($0.21) per share, with a total value of £112,280 ($150,772.12). Insiders own 22.43% of the company's stock.
Creo Medical Group Company Profile
(
Get Free Report)
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.
Read More
Before you consider Creo Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.
While Creo Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
